Concepedia

Birgit Bossenmaier

BB

Statistics

Publications

28

Citations

2.2K

H-Index

20

Active since

1993

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

University of Tübingen

Max Planck Institute of Biochemistry

Ludwig-Maximilians-Universität München

Birgit Bossenmaier is an author at Roche (Switzerland) specializing in oncology, life sciences, and cell signaling.

ORCID

Publications per year

1993–2020

28

Publications

28

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

Werner Scheuer, Thomas Friess, Helmut Burtscher et al. · Cancer Research · 2009 · 626 citations · Full text

, , +17

Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

G Kroder, Birgit Bossenmaier, Monika Kellerer et al. · Journal of Clinical Investigation · 1996 · 218 citations · Full text

, , +17

Differential activities of protein tyrosine phosphatases in intact cells.

Reiner Lammers, Birgit Bossenmaier, D E Cool et al. · Journal of Biological Chemistry · 1993 · 156 citations · Full text

, , +17

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab

Christian A. Gerdes, Valeria Nicolini, Sylvia Herter et al. · Clinical Cancer Research · 2012 · 115 citations · Full text

, , +17

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

Christian Mirschberger, Christian Schiller, Michael Schräml et al. · Cancer Research · 2013 · 103 citations · Full text

, , +14

1–5 of 28